Skip to main content

Table 2 Baseline demographics, risk factors and clinical characteristics

From: Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients

  Male Female
  Statin
(n = 5279)
Statin + EZ
(n = 6016)
Statin
(n = 5029)
Statin + EZ
(n = 5470)
Mean age, years (SD) 58.4 (11.22) 59.2 (11.14) 60.0 (11.23) 60.7 (11.01)
Age, n (%)     
   < 65 years 3556 (67.4) 3909 (65.0) 3126 (62.2) 3341 (61.1)
   65-74 years 1361 (25.8) 1614 (26.8) 1457 (29.0) 1557 (28.5)
   ≥75 years 362 (6.9) 493 (8.2) 446 (8.9) 572 (10.5)
Caucasian, n (%) 4549 (86.2) 5187 (86.2) 4141 (82.3) 4519 (82.6)
BMI < 30 kg/m2 (%) 3287 (63.2) 3728 (62.8) 2721 (55.0) 3056 (56.7)
CHD, n (%) 2129 (40.3) 2614 (43.5) 1181 (23.5) 1501 (27.5)
Diabetes, n (%) 1491 (28.2) 1732 (28.8) 1591 (31.6) 1727 (31.6)
Metabolic syndrome 1912 (46.5) 2112 (45.8) 2321 (54.7) 2406 (53.6)
Ongoing Statin*, n (%) 2271 (43.0) 2935 (48.8) 1780 (35.4) 2310 (42.2)
Least squares mean (SD) (n = 5279) (n = 6016) (n = 5029) (n = 5470)
LDL-C (mg/dL) 147.0 (40.3) 144.4 (39.8) 156.4 (41.7) 154.2 (42.5)
HDL-C (mg/dL) 45.8 (10.5) 45.7 (10.3) 53.4 (12.7) 53.7 (13.0)
non-HDL-C (mg/dL) 180.2 (44.5) 177.5 (44.0) 190.1 (45.8) 187.6 (46.4)
TC (mg/dL) 226.0 (44.0) 223.2 (43.6) 243.6 (45.7) 241.3 (46.2)
Triglycerides (mg/dL) 150.0 (88.1) 151.0 (87.9) 156.5 (90.2) 154.0 (90.7)
Apo B (mg/dL) 142.5 (32.7) 141.3 (32.3) 147.9 (34.0) 146.4 (34.4)
Apo AI (mg/dL) 146.3 (23.2) 146.4 (23.8) 164.2 (27.5) 165.0 (28.0)
hs-CRP (mg/L) 1.8 (2.7) 1.8 (2.7) 2.7 (4.1) 2.8 (4.1)
non-HDL-C/HDL-C 4.1 (1.5) 4.1 (1.4) 3.8 (1.4) 3.7 (1.4)
Apo B/Apo AI 1.0 (0.3) 1.0 (0.3) 0.9 (0.3) 0.9 (0.3)
LDL-C/HDL-C 3.4 (1.2) 3.3 (1.2) 3.1 (1.1) 3.0 (1.1)
TC/HDL-C 5.2 (1.5) 5.1 (1.4) 4.8 (1.4) 4.7 (1.4)
  1. Apo = Apolipoprotein; BMI = body mass index; CHD = coronary heart disease; EZ = ezetimibe; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; hs-CRP = high-sensitivity C-reactive protein; SD = standard deviation; TC = total cholesterol
  2. *Patients who entered a study who were already receiving statin treatment prior to screening
  3. presented as median values (robust SD); p-values based on ANOVA model using Tukey scores transformed values with term for gender.